(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr7.94 | 3.46% | 61.1% |
| LNA SANTE (LNA.PA) | €16.94 | 2.54% | 9.08% |
| ESSILORLUXOTTICA (EL.PA) | €183.66 | 1.92% | 6.44% |
| BIOMERIEUX (BIM.PA) | €97.80 | 0.87% | 9.87% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.49.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 16.2. Meaning, the purchaser of the share is investing kr16.2 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
CONTEXTVISION’s EBITDA is 49.39.
Sales Growth
CONTEXTVISION’s sales growth for the current quarter is 29.8%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Nov 2, 2023, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 3.46%.
More news about CONTEXTVISION.
2. LNA SANTE (LNA.PA)
2.54% Forward Dividend Yield and 9.08% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 7.43. Meaning, the purchaser of the share is investing €7.43 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.
Volume
Today’s last reported volume for LNA SANTE is 10290 which is 132.33% above its average volume of 4429.
More news about LNA SANTE.
3. ESSILORLUXOTTICA (EL.PA)
1.92% Forward Dividend Yield and 6.44% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €5.22.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 35.18. Meaning, the purchaser of the share is investing €35.18 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.44%.
More news about ESSILORLUXOTTICA.
4. BIOMERIEUX (BIM.PA)
0.87% Forward Dividend Yield and 9.87% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.25.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 30.09. Meaning, the purchaser of the share is investing €30.09 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.87%.
Volume
Today’s last reported volume for BIOMERIEUX is 12946 which is 85.65% below its average volume of 90259.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 6, 2023, the estimated forward annual dividend rate is 0.85 and the estimated forward annual dividend yield is 0.87%.
More news about BIOMERIEUX.
